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36 (-9.50 [-10.97, -8.04; P< 0.0001], n= 584). PRIMUS ALS scores also improved from 
baseline (mean change [95% CI]) to Week 12 (-2.47 [-2.83, -2.11; P< 0.0001], n= 501) 
and Week 36 (-1.53 [-1.96, -1.10; P< 0.0001], n= 437) in patients on treatment. Results 
for the change from baseline to Week 48 for outcomes, including the SF-36 PCS, in 
patients on treatment will be presented. ConClusions: PR-fampridine, which 
improves walking in MS, shows benefits on HRQoL through 36 weeks of treatment.
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objeCtives: The current prevalence of Multiple Sclerosis (MS) in Slovakia ranges 
from 100 till 150 cases per 100 000 population Being a typical chronic disease 
with tendency of progression, MS can have a great impact on quality of life (QoL). 
The objective of this paper was to find out the level of QoL in patients with MS in 
Slovakia. Methods: The primary method used for the analysis of QoL was the 
presence of disability period and combined questionnaire consisting of 4 parts: 
A. Demography and socioeconomics (13 items), B. Generic questionnaire (SF-36), 
C. Visual scale (4 items), D. Complementary (information and habits, 13 items). There 
were 2 groups of patients. Group A: 41 (29 women, 12 men) patients were treated by 
conventional therapy. Group B: the 41 (32 women, 9 men) patients were treated by 
moderns disease modifying treatment and biological therapy (Betaferon, Avonex, 
Rebif, Tysabri, Gilenya, Copaxone). The average age in the group A was 50.59 vs 
41.82 years in the group B. Results: Disability was 9,39 months per one patient 
per year in group A vs 5,02 in group B, loss of income was 123 vs 165 € per person, 
the expectations of the future was 2,39 vs 2,41 (in the five degrees scale). Present 
level of QoL was identified as 5.29 vs 4,34 on the scale of 10, while in the time of the 
MS diagnosis it was 3,29 vs 2,15. QoL was 8.68 vs 8,17 in the time without SM and 
9,24 vs 8,29 in the total optimal state of health. ConClusions: The treatment of 
MS by conventional or disease modifying therapy (DMT) had a significant impact 
on QoL. The modern DMT had the higher statistical influence as on physical health 
(45,65 vs 28,23) so on mental health (51,65 vs 33,01) in comparison with the patients 
treated by conventional therapy.
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objeCtives: To determine the correlation between the Montgomery-Asberg 
Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II) 
scores in patients with drug-resistant focal epilepsy (DRE) in comparison with 
patients with controlled focal epilepsy (CFE). Methods: Observational, cross-
sectional study performed in patients with focal epilepsy (FE) with and without 
DRE, ≥ 18 years. Presence and severity of depression were measured using validated 
Spanish versions of the Montgomery-Asberg Depression Rating Scale (MADRS) and 
the Beck Depression Inventory (BDI-II). In order to know the correlation between 
MADRS and BDI-II, two different criteria were used; degree of association obtained 
on prevalence of depression and correlation between scores from both scales, using 
Pearson correlation coefficient. Results: 515 patients (DRE= 248) were included. 
Using the MADRS scale, prevalence of depression in the DRE group was almost 
double than in the CFE group (59.3% vs. 30.3% using unadjusted data and 62.1% vs. 
32.6% using adjusted data; p< 0.001). Similar results were seen with the BDI, with 
an overall depression rate of 48.1% using the ≥ 10 point threshold, and considerably 
higher rates of depression in the DRE group compared to CFE patients (61.9 % vs. 
35.3% using unadjusted data, and 64.8% vs. 37.2% using adjusted data; p< 0.001). 
Correlation between MADRS and BDI-II was 24,4 % (65/266) in CFE and 51,0% 
(126/247) in DRE patients, according to the degree of association; while the Pearson 
correlation coefficient between the two scales was high, at r= 0.80. ConClusions: 
MADRS and BDI-II showed a positive correlation; the score increment of one scale 
is directly proportional to the increase of the other scale. In both cases, the strong-
est contributor to higher MADRS and BDI-II scores was having a previous clinical 
diagnosis of depression but being untreated for the condition.
Neurological DisorDers – health care use & Policy studies
PND54
aDDitioNal cliNical BeNefit for PatieNt relevaNt eNDPoiNts: 
iNvestMeNt DisiNceNtives By aMNog iN the exaMPle of ParkiNsoN’s 
Disease
Walzer S.1, Holbein B.2
1MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2University of 
Bremen, Bremen, Germany
objeCtives: After the introduction of the new German law AMNOG a statistically 
significant and clinically meaningful difference in patient relevant endpoints are 
required in order to achieve a (significant) clinical benefit for a new (drug) ther-
apy. The question remains if such an incentive is sufficient in all disease areas 
for positive investment decisions for the pharmaceutical industry. Methods: In 
Parkinson’s disease motor fluctuations and dyskinesias are two major patient rel-
evant outcomes. Different target profiles for a clinical development programme 
of a theoretical new treatment were developed including scenarios following the 
regulatory guidelines only, an efficacy-driven programme and one including the 
above mentioned key patient relevant endpoints. An investment decision model was 
developed based on these profiles with respect to additional clinical benefit by the 
joint federal committee and premium pricing in Germany were assessed. Results: 
Positive investment decisions were possible for the regulatory and efficacy-driven 
objeCtives: DMTs constitute an important backbone of MS treatment. To inves-
tigate Health Related Quality of Life (HRQOL) and patient adherence rates to the 
approved DMTs for RRMS among geographically and culturally diverse patient 
populations, a multinational study was to be implemented. Operational and sci-
entific outcomes are presented. Methods: The study was designed as an obser-
vational, multicenter, multinational post marketing study. Patients and physicians 
received paper questionnaires evaluating adherence to DMTs approved at the time 
of the study. HRQOL (MusiQol) and a Neuropsychological Questionnaire (MSNQ) 
also were applied. Results: The study was implemented in 22 countries. Special 
challenges: cross-cultural CRF design, country-specific recruitment procedures for 
sites and patients, country/site specific contractual arrangements. Ethical approval 
was collected from 70 local and 15 central institutions. Patient recruitment was 
performed via 176 neurologists (hospital and office based). In total, 2.566 patients 
were enrolled within 6 months. Average treatment duration / observational period 
covered 31 months. The study findings revealed that 75% of the patients were adher-
ent (i.e. not missing an injection or changing dose). 12.6% of all patients forgot to 
administer injections compared to 50% of non-adherent patients. Compared to 
non-adherent patients, adherent patients showed shorter disease duration (adher-
ent: median 6.0 yrs; non-adherent: Median 7.0 yrs.), significant shorter treatment 
time (30.0 months vs. 36.0 months; p< 0,001) and a better MSNQ score (18.0 vs. 22.0; 
p< 0,001). ConClusions: For implementing a global multicenter center impor-
tant issues include: linguistic specifics for CRF development, availability of medical 
centers for site recruitment, country specific legal and ethical requirements, care-
ful organization and sharing of responsibilities between the study coordination 
center and local affiliates. Non-adherence to DMT in RRMS was demonstrated to 
be mainly caused by injection problems; adherent patients showed better clinical 
and HRQOL outcomes.
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objeCtives: To examine the quality of life (QoL) of the Alzheimer’s Disease (AD) 
patients in relation to disease progression during the five-year ALSOVA follow-up 
study. Methods: The baseline sample consisted of 240 subjects with very mild 
or mild AD, 65 years or older, from three Finnish hospital districts. The subjects 
were recruited between 2002 and 2006, and were followed-up for five years. Three 
separate patient-reported wellbeing and life satisfaction instruments were used as 
proxy variables for QoL: a generic, preference-based health-related quality-of-life 
instrument, 15D; an AD -specific wellbeing measure, AD-QOL; and a VAS-based 
life satisfaction scale. AD progression was evaluated with the Clinical Dementia 
Rating (CDR). Both CDR Sum-of-Boxes (CDR-SOB) and global rating were used in the 
analysis. Generalized linear mixed models with hierarchical structure were applied 
to account for repeated measures and possible clustering by the hospital district. 
Data were adjusted for age, sex and years of education. Results: On average, none 
of the three outcome measures demonstrated statistically significant changes over 
time during the five year follow-up. However, when the outcomes were examined 
in relation to AD progression, both CDR-SOB and CDR global rating demonstrated 
statistically significant association between the severity of AD and lower QoL on all 
three outcome measures. However, when using CDR global rating to define disease 
progression, we observed meaningful impairments in QoL variables only in the 
patients with severe AD (CDR 3). ConClusions: Severe AD has a considerable 
impact on patients’ QOL through substantial impairments in wellbeing and life 
satisfaction. Evidence suggest that CDR-SOB is a potential continuous measure of 
AD severity. While CDR-SOB is strongly associated with decrease QoL measures, our 
observations indicate that it is unlikely to be linearly correlated with QoL. Thus, the 
use of CDR-SOB as a determinant of QoL needs to be examined further.
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objeCtives: Prolonged-release (PR) fampridine tablets (dalfampridine extended 
release in US) improve walking in some patients with multiple sclerosis (MS). The 
ENABLE study assessed the effect of long-term PR-fampridine treatment on health-
related quality of life (HRQoL) in MS patients with walking impairment. Methods: 
ENABLE is an open-label, 48-week study to evaluate the effect of PR-fampridine 10 
mg twice daily on HRQoL in MS patients. Patients completed the Timed 25-Foot 
Walk (T25FW) at baseline and Weeks 2 and 4, and the 12-item MS Walking Scale 
(MSWS-12) at baseline and Week 4. Patients with any improvement in T25FW 
speed at both Weeks 2 and 4, and any improvement in MSWS-12 score at Week 
4 remained on treatment. HRQoL measures are assessed at baseline and Weeks 
12, 24, 36, and 48, and include the Short-Form Health Survey (SF-36), Multiple 
Sclerosis Impact Scale (MSIS-29), and the Patient Reported Indices for MS Activity 
Limitations Scale (PRIMUS ALS). The primary endpoint is the change from baseline 
in the SF-36 physical component summary (PCS) score at each visit in patients on 
treatment. Results: At Week 4, 704 patients (78.1% of total enrollment [N= 901]) 
met the criteria to remain on treatment. Interim results at 36 weeks in patients 
on treatment show improvement from baseline (mean change [95% CI]) in MSIS-
29 Physical scores to Week 12 (-12.99 [-14.24, -11.74; P< 0.0001], n= 672) and Week 
